Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Författare
Summary, in English
The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the development of malignant melanoma. An increased risk of melanoma in sildenafil users was recently reported.
Avdelning/ar
Publiceringsår
2015
Språk
Engelska
Sidor
2449-2455
Publikation/Tidskrift/Serie
JAMA: The Journal of the American Medical Association
Volym
313
Issue
24
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
American Medical Association
Ämne
- Other Clinical Medicine
Status
Published
ISBN/ISSN/Övrigt
- ISSN: 1538-3598